Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed Patients With Chronic Hepatitis B

Trial Profile

A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed Patients With Chronic Hepatitis B

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vebicorvir (Primary) ; Entecavir; Tenofovir alafenamide; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Assembly Biosciences
  • Most Recent Events

    • 26 Jun 2022 Results assessing clinical evaluation of VBR 's drug-drug interaction (DDI) potential from Phase 1 (Study 103 ) and Phase 2a (NCT03577171, NCT03576066) studies, presented at The International Liver Congress 2022.
    • 08 Jun 2022 According to an Assembly Biosciences media release, data from this study will be presented at the International Liver Congress, the Annual Meeting of the European Association for the Study of the Liver (EASL).
    • 20 Apr 2022 Results published in the Journal of Hepatology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top